🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Impact of IBD Activity on Frailty in Patients Over 60 Years

Recruitingn/aAges 60 Years - anyAllGrupo Espanol de Trabajo en Enfermedad de Crohn y…
NCT06844318 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this observational, multicenter, descriptive, prospective, and longitudinal study is to evaluate the impact of IBD activity on frailty in a prospective and longitudinal cohort of patients with IBD, and also to assess the impact of frailty on the risk of hospitalization and mortality in patients with IBD aged ≥60 years. The main questions it aims to answer are: 1. Can frailty and consequently the risk of complications (adverse events, hospitalization, and mortality) be reversed through proactive treatment in frail patients with active inflammatory bowel disease? 2. Which frailty index is the most effective for predicting the risk of complications in patients with active inflammatory bowel disease? At inclusion, clinical frailty indices will be calculated. Additionally, clinical variables related to IBD and comorbidities will be recorded. During follow ups visits frailty, com

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients aged ≥60 years with IBD (Crohn's disease or ulcerative colitis) diagnosed according to ECCO criteria and under follow-up in the IBD units of participating centers. * Initiation of medical treatment (oral mesalazine, topical or systemic corticosteroids, immunosuppressants, and/or biologics) due to clinical activity based on PRO2 scales (UC: PRO \>4; CD: PRO2 \>14) and/or biological activity (fecal calprotectin ≥500 mg/kg, C-reactive protein ≥10 mg/L). * Signed informed consent for inclusion. Exclusion Criteria: * Lack or withdrawal of informed consent. * Unclassified/indeterminate colitis. * Change in medical treatment solely due to adverse events. * Initiation of treatment only with salicylates and/or topical steroids for disease activity. * Treatment intensification to manage disease activity. * Patients with an ostomy. * Comorbidities with a life expectancy of less than one year.
💊

What it tests

  • Not listed
📍

Where

34 sites
Hospital Universitario Araba
Vitoria-Gasteiz, Spain
Hospital Germans Trias i Pujol
Badalona, Spain
Hospital de Bellvitge
L'Hospitalet de Llobregat, Spain
Althaia Manresa
Manresa, Spain
Hospital del Mataró
Mataró, Spain
Consorci Sanitari de Terrassa
Terrassa, Spain
Hospital Mútua de Terrassa
Terrassa, Spain
Hospital Viladecans
Viladecans, Spain

…and 26 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy